Special Issue

Pluripotent Stem Cell Biology and Engineering

Message from the Guest Editors

Pluripotent stem cells have proven to be powerful tools in bioengineering due to their enormous potential regarding disease modelling, drug discovery and cell therapy. Strategies towards a more efficient and reliable recapitulation of embryonic development are still required, and this can be achieved through further study of pluripotency mechanisms and methods to direct pluripotent stem cells towards a specific fate.

By carefully controlling the culture microenvironment, either using biochemical or biophysical cues, in combination with different bioengineering approaches, either at a cellular, multicellular, and multiorgan levels, it will be possible to fully comprehend and recreate the embryonic development, accelerating the discovery of novel applications and strategies for human pluripotent stem cells and their derivatives. This includes high-throughput screening for efficient and personalized new drugs, platforms that provide a better understanding of disease mechanisms or even the development of robust cell therapy products.

We are welcoming original research articles, review articles and short communications.

Guest Editors

Dr. Claudia Miranda

- 1. Department of Bioengineering and iBB Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
- Associate Laboratory i4HB Institute for Health and Bioeconomy at Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal

Dr. Paola Sanjuan Alberte

- Department of Bioengineering and iBB Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
- Associate Laboratory i4HB Institute for Health and Bioeconomy at Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal 3. Regenerative Medicine and Cellular Therapies, School of Pharmacy, University of Nottingham, University Park, NG7 2RD, UK

Deadline for manuscript submissions

closed (31 December 2022)



Bioengineering

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 5.3 Indexed in PubMed



mdpi.com/si/103350

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

mdpi.com/journal/bioengineering





Bioengineering

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 5.3 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

